BR112014017735A8 - Compostos derivados de amida heterocíclicos como antagonistas do receptor de p2x7, composição farmacêutica, e, uso de um composto - Google Patents
Compostos derivados de amida heterocíclicos como antagonistas do receptor de p2x7, composição farmacêutica, e, uso de um compostoInfo
- Publication number
- BR112014017735A8 BR112014017735A8 BR112014017735A BR112014017735A BR112014017735A8 BR 112014017735 A8 BR112014017735 A8 BR 112014017735A8 BR 112014017735 A BR112014017735 A BR 112014017735A BR 112014017735 A BR112014017735 A BR 112014017735A BR 112014017735 A8 BR112014017735 A8 BR 112014017735A8
- Authority
- BR
- Brazil
- Prior art keywords
- receptor antagonists
- compound
- pharmaceutical composition
- heterocyclic amide
- amide derivative
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 102100037602 P2X purinoceptor 7 Human genes 0.000 title abstract 2
- 101710189965 P2X purinoceptor 7 Proteins 0.000 title abstract 2
- 150000001408 amides Chemical class 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 heterocyclic amide Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IBPCT/IB2012/050282 | 2012-01-20 | ||
IB2012050282 | 2012-01-20 | ||
PCT/IB2013/050479 WO2013108227A1 (en) | 2012-01-20 | 2013-01-18 | Heterocyclic amide derivatives as p2x7 receptor antagonists |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112014017735A2 BR112014017735A2 (pt) | 2017-06-27 |
BR112014017735A8 true BR112014017735A8 (pt) | 2017-12-26 |
BR112014017735B1 BR112014017735B1 (pt) | 2022-06-28 |
Family
ID=47757670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014017735-0A BR112014017735B1 (pt) | 2012-01-20 | 2013-01-18 | Compostos derivados de amida heterocíclicos como antagonistas do receptor de p2x7, composição farmacêutica, e, uso de um composto |
Country Status (23)
Country | Link |
---|---|
US (1) | US9409917B2 (pt) |
EP (1) | EP2804865B1 (pt) |
JP (1) | JP6111268B2 (pt) |
KR (1) | KR102033190B1 (pt) |
CN (1) | CN104066737B (pt) |
AR (1) | AR089753A1 (pt) |
AU (1) | AU2013210682B2 (pt) |
BR (1) | BR112014017735B1 (pt) |
CA (1) | CA2863228C (pt) |
CL (1) | CL2014001772A1 (pt) |
EA (1) | EA024204B1 (pt) |
ES (1) | ES2563189T3 (pt) |
HK (1) | HK1203932A1 (pt) |
IL (1) | IL233662A0 (pt) |
MA (1) | MA35893B1 (pt) |
MX (1) | MX336247B (pt) |
NZ (1) | NZ628910A (pt) |
PH (1) | PH12014501415A1 (pt) |
PL (1) | PL2804865T3 (pt) |
SG (1) | SG11201403933UA (pt) |
TW (1) | TWI576347B (pt) |
WO (1) | WO2013108227A1 (pt) |
ZA (1) | ZA201406085B (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101995088B1 (ko) | 2011-07-22 | 2019-07-02 | 이도르시아 파마슈티컬스 리미티드 | P2x7 수용체 길항제로서의 헤테로시클릭 아미드 유도체 |
BR112015013463B1 (pt) | 2012-12-12 | 2022-06-14 | Idorsia Pharmaceuticals Ltd | Derivados de carboxamida indol como antagonistas do receptor de p2x7 |
ES2614495T3 (es) | 2012-12-18 | 2017-05-31 | Actelion Pharmaceuticals Ltd. | Derivados de indol carboxamida como antagonistas del receptor P2X7 |
KR102220847B1 (ko) | 2013-01-22 | 2021-02-26 | 이도르시아 파마슈티컬스 리미티드 | P2x7 수용체 길항제로서의 헤테로시클릭 아미드 유도체 |
ES2616114T3 (es) | 2013-01-22 | 2017-06-09 | Actelion Pharmaceuticals Ltd. | Derivados de amida heterocíclica como antagonistas del receptor P2X7 |
WO2015148802A1 (en) * | 2014-03-26 | 2015-10-01 | The Children's Medical Center Corporation | Celastrol and derivatives for the treatment of obesity |
SG11201906627YA (en) * | 2017-03-13 | 2019-08-27 | Raqualia Pharma Inc | Tetrahydroquinoline derivatives as p2x7 receptor antagonists |
WO2019144041A1 (en) | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
US11964967B2 (en) | 2018-06-26 | 2024-04-23 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
KR20240015622A (ko) | 2021-03-04 | 2024-02-05 | 싸이토키네틱스, 인코포레이티드 | 심장 근절 억제제 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU774526B2 (en) | 1999-04-09 | 2004-07-01 | Astrazeneca Ab | Adamantane derivatives |
SE9904505D0 (sv) | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
TWI258462B (en) | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
GB0013737D0 (en) | 2000-06-07 | 2000-07-26 | Astrazeneca Ab | Novel compounds |
PA8557501A1 (es) | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
WO2003042190A1 (en) | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
SE0103836D0 (sv) | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Novel compounds |
SE0200920D0 (sv) | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
PA8591801A1 (es) | 2002-12-31 | 2004-07-26 | Pfizer Prod Inc | Inhibidores benzamidicos del receptor p2x7. |
AU2003288640A1 (en) | 2002-12-31 | 2004-07-22 | Pfizer Products Inc. | Benzamide inhibitors of the p2x7 receptor |
SE0300480D0 (sv) | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
DE602004005033T2 (de) | 2003-05-12 | 2007-08-09 | Pfizer Products Inc., Groton | Benzamidinhibitoren des p2x7-rezeptors |
GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
SE0302139D0 (sv) | 2003-07-28 | 2003-07-28 | Astrazeneca Ab | Novel compounds |
CN1875361A (zh) * | 2003-10-30 | 2006-12-06 | 皇家飞利浦电子股份有限公司 | 预测输入的方法 |
JP2007535553A (ja) | 2004-04-29 | 2007-12-06 | アボット・ラボラトリーズ | アミノ−テトラゾール類縁体および使用方法 |
SA05260265A (ar) | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
SE0402925D0 (sv) | 2004-11-30 | 2004-11-30 | Astrazeneca Ab | Novel Compounds |
US20080146612A1 (en) | 2005-01-27 | 2008-06-19 | Astrazeneca Ab | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor |
US7238702B2 (en) | 2005-02-10 | 2007-07-03 | Bristol-Myers Squibb Company | Dihydroquinazolinones as 5HT modulators |
US7297700B2 (en) | 2005-03-24 | 2007-11-20 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
WO2007055374A1 (ja) * | 2005-11-14 | 2007-05-18 | Mitsubishi Tanabe Pharma Corporation | 骨粗鬆症治療剤 |
US20100298285A1 (en) | 2006-03-16 | 2010-11-25 | Kelly Michael G | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof |
US8779144B2 (en) | 2006-03-16 | 2014-07-15 | Evotec (Us) Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
CA2645652A1 (en) | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
WO2007109201A2 (en) | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
WO2007109172A2 (en) | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
TWI464148B (zh) | 2006-03-16 | 2014-12-11 | Evotec Us Inc | 作為p2x7調節劑之雙環雜芳基化合物與其用途 |
GB0611154D0 (en) | 2006-06-06 | 2006-07-19 | Glaxo Group Ltd | Novel receptor antagonists and their methods of use |
DE602007010781D1 (de) | 2006-06-06 | 2011-01-05 | Glaxo Group Ltd | N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid-derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration |
DK2049478T3 (da) | 2006-07-06 | 2012-07-09 | Glaxo Group Ltd | Substituerede N-phenylmethyl-5-oxoprolin-2-amider som P2X7-receptorantagonister og fremgangsmåder til anvendelse deraf |
MX2009005478A (es) | 2006-11-27 | 2009-08-12 | Lundbeck & Co As H | Derivados de heteroarilamida. |
TW200838516A (en) | 2007-01-31 | 2008-10-01 | Merck & Co Inc | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
CN101686680B (zh) | 2007-03-09 | 2015-12-09 | 伊沃泰克美国股份有限公司 | 作为p2x7调节剂的双环杂芳基化合物及其用途 |
MX2009010059A (es) | 2007-03-22 | 2009-10-12 | Astrazeneca Ab | Derivados de quinolina para el tratamiento de enfermedades inflamatorias. |
GB0705882D0 (en) | 2007-03-27 | 2007-05-02 | Glaxo Group Ltd | Novel compounds |
US20100168171A1 (en) | 2007-03-28 | 2010-07-01 | Paul John Beswick | Piperidinone Carboxamide Derivatives as P2X7 Modulators |
US20100144727A1 (en) | 2007-03-29 | 2010-06-10 | Paul John Beswick | Oxazolidine and Morpholine Carboxamide Derivatives as P2X7 Modulators |
KR20090127435A (ko) | 2007-04-03 | 2009-12-11 | 글락소 그룹 리미티드 | P2x7 조절제로서의 이미다졸리딘 카르복스아미드 유도체 |
CN103204852A (zh) | 2007-04-10 | 2013-07-17 | H.隆德贝克有限公司 | 作为p2x7拮抗剂的杂芳基酰胺类似物 |
JP2010523623A (ja) | 2007-04-11 | 2010-07-15 | グラクソ グループ リミテッド | P2x7調節因子としてのピラゾール誘導体 |
US20110046137A1 (en) | 2007-05-10 | 2011-02-24 | Glaxo Group Limited | Pyrazole Derivatives as P2X7 Modulators |
UA105758C2 (uk) | 2007-07-19 | 2014-06-25 | Х. Луннбек А/С | 5-членні гетероциклічні аміди та споріднені сполуки |
EA020332B1 (ru) * | 2007-08-10 | 2014-10-30 | Х. Лундбекк А/С | Аналоги гетероариламидов |
PE20091036A1 (es) | 2007-11-30 | 2009-08-15 | Astrazeneca Ab | Derivado de quinolina como antagonista del receptor p2x7 |
WO2009074518A1 (en) | 2007-12-12 | 2009-06-18 | Glaxo Group Limited | Combinations of prolinamide p2x7 modulators with further therapeutic agents |
GB0724258D0 (en) | 2007-12-12 | 2008-01-30 | Glaxo Group Ltd | Novel combinations |
GB0724625D0 (en) | 2007-12-18 | 2008-01-30 | Glaxo Group Ltd | Novel compounds |
WO2009077559A2 (en) | 2007-12-18 | 2009-06-25 | Glaxo Group Limited | 5-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators |
WO2009108551A2 (en) | 2008-02-25 | 2009-09-03 | H. Lundbeck A/S | Heteroaryl amide analogues |
EA022505B1 (ru) | 2008-03-25 | 2016-01-29 | Эффектис Фармасьютиклз Аг | Новые p2x7r антагонисты и их применение |
ATE533762T1 (de) | 2008-04-22 | 2011-12-15 | Janssen Pharmaceutica Nv | Chinolin- oder isochinolinsubstituierte p2x7- antagonisten |
PT2243772E (pt) | 2009-04-14 | 2012-03-28 | Affectis Pharmaceuticals Ag | Novos antagonistas de p2x7r e sua utilização |
GB0919594D0 (en) | 2009-11-09 | 2009-12-23 | Glaxo Group Ltd | Compounds |
US20120157494A1 (en) | 2010-12-16 | 2012-06-21 | Harris Iii Ralph New | Isoindolyl compounds |
CA2824415A1 (en) | 2011-02-22 | 2012-08-30 | Actelion Pharmaceuticals Ltd | Benzamide derivatives as p2x7 receptor antagonists |
WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
KR101995088B1 (ko) * | 2011-07-22 | 2019-07-02 | 이도르시아 파마슈티컬스 리미티드 | P2x7 수용체 길항제로서의 헤테로시클릭 아미드 유도체 |
BR112015013463B1 (pt) | 2012-12-12 | 2022-06-14 | Idorsia Pharmaceuticals Ltd | Derivados de carboxamida indol como antagonistas do receptor de p2x7 |
ES2614495T3 (es) | 2012-12-18 | 2017-05-31 | Actelion Pharmaceuticals Ltd. | Derivados de indol carboxamida como antagonistas del receptor P2X7 |
KR102220847B1 (ko) | 2013-01-22 | 2021-02-26 | 이도르시아 파마슈티컬스 리미티드 | P2x7 수용체 길항제로서의 헤테로시클릭 아미드 유도체 |
ES2616114T3 (es) | 2013-01-22 | 2017-06-09 | Actelion Pharmaceuticals Ltd. | Derivados de amida heterocíclica como antagonistas del receptor P2X7 |
-
2013
- 2013-01-18 JP JP2014552736A patent/JP6111268B2/ja not_active Expired - Fee Related
- 2013-01-18 WO PCT/IB2013/050479 patent/WO2013108227A1/en active Application Filing
- 2013-01-18 SG SG11201403933UA patent/SG11201403933UA/en unknown
- 2013-01-18 PL PL13707053T patent/PL2804865T3/pl unknown
- 2013-01-18 TW TW102102130A patent/TWI576347B/zh not_active IP Right Cessation
- 2013-01-18 ES ES13707053.8T patent/ES2563189T3/es active Active
- 2013-01-18 MX MX2014008736A patent/MX336247B/es unknown
- 2013-01-18 US US14/373,338 patent/US9409917B2/en active Active
- 2013-01-18 CN CN201380005966.8A patent/CN104066737B/zh not_active Expired - Fee Related
- 2013-01-18 BR BR112014017735-0A patent/BR112014017735B1/pt not_active IP Right Cessation
- 2013-01-18 CA CA2863228A patent/CA2863228C/en active Active
- 2013-01-18 AU AU2013210682A patent/AU2013210682B2/en not_active Ceased
- 2013-01-18 EP EP13707053.8A patent/EP2804865B1/en active Active
- 2013-01-18 EA EA201400822A patent/EA024204B1/ru not_active IP Right Cessation
- 2013-01-18 KR KR1020147022934A patent/KR102033190B1/ko active IP Right Grant
- 2013-01-18 AR ARP130100155A patent/AR089753A1/es unknown
- 2013-01-18 NZ NZ628910A patent/NZ628910A/en not_active IP Right Cessation
-
2014
- 2014-06-20 PH PH12014501415A patent/PH12014501415A1/en unknown
- 2014-07-01 CL CL2014001772A patent/CL2014001772A1/es unknown
- 2014-07-16 IL IL233662A patent/IL233662A0/en unknown
- 2014-07-31 MA MA37252A patent/MA35893B1/fr unknown
- 2014-08-19 ZA ZA2014/06085A patent/ZA201406085B/en unknown
-
2015
- 2015-05-07 HK HK15104330.4A patent/HK1203932A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014017735A8 (pt) | Compostos derivados de amida heterocíclicos como antagonistas do receptor de p2x7, composição farmacêutica, e, uso de um composto | |
BR112014030173A8 (pt) | Composto derivado de benzimidazol-prolina, e, composição farmacêutica | |
BR112015013463A2 (pt) | derivados de carboxamida indol como antagonistas do receptor de p2x7 | |
BR112015022993A8 (pt) | inibidores de jak2 e alk2 e métodos para sua utilização. | |
CU20100238A7 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato | |
MX338707B (es) | Compuestos heterociclicos activadores de proteina cinasa activada por 5'-amp (ampk) y metodos para emplearlos. | |
BR112012000763B8 (pt) | compostos derivados de piridin-4-il, composição farmacêutica, e, usos de um composto | |
BR112014010617A8 (pt) | Derivados de 2-(1,2,3-triazol-2-il)benzamida e 3-(1,2,3-triazol-2-il)picolinamida como antagonistas do receptor de orexina | |
ECSP10010419A (es) | Derivados heterocíclicos de urea y métodos de uso de los mismos-211 | |
BR112019001551A2 (pt) | moduladores do receptor de piperidina cxcr7 | |
CO6351723A2 (es) | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1 | |
ECSP10010664A (es) | Derivados de urea heterocíclicos para el tratamiento de infecciones bacterianas | |
PH12015502632A1 (en) | Cxcr7 receptor modulators | |
BR112017015093A2 (pt) | derivados de hidroxialquil-piperazina como moduladores do receptor cxcr3 | |
UY32856A (es) | Derivados heterocíclicos de urea y métodos de uso de los mismos | |
BR112016001876A2 (pt) | composto de benzoxaborol tricíclico, método de preparação e uso do mesmo | |
PH12016500322A1 (en) | Amide derivatives as lysophosphatidic acid receptor antagonists | |
BR112015024971A2 (pt) | derivados de n-(2,3-di-hidro-1h-pirrolo[2,3-b]piridin-5-il)-4-quinazolinamina e n-(2,3-di-hidro-1h-indol-5-il)-4-quinazolinamina como inibidores de perk | |
BR112014031755A8 (pt) | Derivados de 1-[m-carboxamido (hetero) aril-metil]-heterociclil-carboxamida | |
BR112017015116A2 (pt) | derivados de (r)-2-metil-piperazina como moduladores do receptor cxcr3 | |
UY32694A (es) | Derivados heterocíclicos de urea y métodos de uso de los mismos | |
BR112016001238A8 (pt) | Derivados de 1-(piperazin-1-il)-2-([1,2,4]triazol-1-il)-etanona, seus usos e composição farmacêutica os compreendendo | |
BR112013017923A8 (pt) | Derivados de 2-metóxi-piridin-4-il | |
BR112015015491A8 (pt) | (tieno[2,3-b][1,5] benzoxazepin-4-il) piperazin-1-ila, seus usos, e composição farmacêutica. | |
CU20100172A7 (es) | Derivados heterocíclicos de urea y métodos de uso de los mismos-211 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: IDORSIA PHARMACEUTICALS LTD (CH) |
|
B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: ACTELION PHARMACEUTICALS LTD (CH) |
|
B25C | Requirement related to requested transfer of rights |
Owner name: ACTELION PHARMACEUTICALS LTD (CH) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: IDORSIA PHARMACEUTICALS LTD (CH) |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/01/2013, OBSERVADAS AS CONDICOES LEGAIS |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 11A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2758 DE 14-11-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |